AIHA, otherwise known as autoimmune hemolytic anemia, is rather uncommon kind of anemia. It causes an individual's body to develop and produce antibodies that turn against the person's own red blood cells. The results in an unhealthy phenomena during which, over time, the premature and permanent destruction of these cells occurs. Liposomal clodronate is a drug that has recently captured the attention of numerous health and medical scientists and researchers, and for this reason it is currently being tested and studied as a possible AIHA treatment.
In many instances, in order to treat the aforementioned disorder successfully, surgery is necessary. Surgical procedures of of any kind can lead to complications, a fact of which most individuals are aware. This is especially true if the person is elderly or has other underlying diseases or health issues.
Those who have disorders of the immune system are typically not good candidates for surgery. Additionally, those who are on certain medications may have a high risk for complications following surgical procedures. These are some of the reasons that research concerning AIHA is focused on discovering new medications for the disorder, rather than more surgical alternatives.
Due to advancements in medical technology, researchers have finally isolated the kind of substance necessary to stop the destruction of red blood cells associated with AIHA. Antimacrophage agents are necessary to impede this activity in patients suffering from this type of anemia.
According to recent research, liposomally encapsulated clodronate can successfully combat the abnormal production of the antibodies that attack one's red blood cells. Additional trials were conducted to find out if these discoveries were truly as positive as the initial studies indicated.
To determine the effectiveness of this substance, a two-year study was completed on laboratory mice. Two groups of mice were given 2 distinctly different antibodies. In both groups, when liposomal clodronate was administered, it substantially lowered the speed at which the red blood cells were attacked. The benefits of the drug lasted as long as two weeks, and it took effect very quickly.
Health experts and researchers are very optimistic with regard to this substance and its possible advantages for those suffering from AIHA. Numerous scientists believe that using this drug may prove as beneficial as a surgical procedure referred to as a therapeutic splenectomy. Naturally, using liposomally encapsulated clodronate is associated with less risks than any type of surgery. The drug may also be beneficial in instances where a fast response to therapy is crucial.
Additionally, therapeutic results were seen when liposomal clodronate was given to individuals for the purpose of suppressing macrophage activity. This is true in a variety of scenarios such as gene therapy, neurological disorders, autoimmune diseases and organ transplants. This is why those suffering from AIHA have every reason to be optimistic regarding the development and marketing of this drug as a treatment for this destructive type of anemia. Additional research, however, is still needed to completely understand all the advantages associated with this substance.
In many instances, in order to treat the aforementioned disorder successfully, surgery is necessary. Surgical procedures of of any kind can lead to complications, a fact of which most individuals are aware. This is especially true if the person is elderly or has other underlying diseases or health issues.
Those who have disorders of the immune system are typically not good candidates for surgery. Additionally, those who are on certain medications may have a high risk for complications following surgical procedures. These are some of the reasons that research concerning AIHA is focused on discovering new medications for the disorder, rather than more surgical alternatives.
Due to advancements in medical technology, researchers have finally isolated the kind of substance necessary to stop the destruction of red blood cells associated with AIHA. Antimacrophage agents are necessary to impede this activity in patients suffering from this type of anemia.
According to recent research, liposomally encapsulated clodronate can successfully combat the abnormal production of the antibodies that attack one's red blood cells. Additional trials were conducted to find out if these discoveries were truly as positive as the initial studies indicated.
To determine the effectiveness of this substance, a two-year study was completed on laboratory mice. Two groups of mice were given 2 distinctly different antibodies. In both groups, when liposomal clodronate was administered, it substantially lowered the speed at which the red blood cells were attacked. The benefits of the drug lasted as long as two weeks, and it took effect very quickly.
Health experts and researchers are very optimistic with regard to this substance and its possible advantages for those suffering from AIHA. Numerous scientists believe that using this drug may prove as beneficial as a surgical procedure referred to as a therapeutic splenectomy. Naturally, using liposomally encapsulated clodronate is associated with less risks than any type of surgery. The drug may also be beneficial in instances where a fast response to therapy is crucial.
Additionally, therapeutic results were seen when liposomal clodronate was given to individuals for the purpose of suppressing macrophage activity. This is true in a variety of scenarios such as gene therapy, neurological disorders, autoimmune diseases and organ transplants. This is why those suffering from AIHA have every reason to be optimistic regarding the development and marketing of this drug as a treatment for this destructive type of anemia. Additional research, however, is still needed to completely understand all the advantages associated with this substance.
About the Author:
Read more about Liposomal Clodronate May Offer Benefits To Those Suffering From Certain Types Of Anemia visiting our website.
No comments:
Post a Comment